StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc.

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$682.65−14.35 (-2.06%)

Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%

Thermo Fisher Scientific Organic Revenue Growth — Specialty Diagnostics by Quarter

Organic Revenue Growth — Specialty Diagnostics (%)

QuarterlyAnnual

Thermo Fisher Scientific Organic Revenue Growth — Specialty Diagnostics: 0.0% in Q3 2026, down 2.0 pts from a year earlier.

Latest, Q3 2026
0.0%
Period ended Sep 30, 2026
Change on a year earlier
-2.0 pts
2.0% in Q3 2025
History
15 quarters
Since Q1 2023
Sources
3
Documents cited below

Where the Q3 2026 figure comes from

“SD: Organic revenue growth (non-GAAP measure) 4% 0% 2% 3% 2% -3% 5% 0%”

Source: Q3 2026 Reconciliation of Financial Information ↗

Reported in IR Financial Reconciliation Package (Business Segment Information) & SEC MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganic Revenue Growth — Specialty Diagnostics (%)Year on yearSource
Q3 2026Sep 30, 20260.0%-2.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q2 2026Jun 30, 20265.0%+5.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q1 2026Mar 31, 2026-3.0%-7.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q4 2025Dec 31, 20253.0%-2.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q3 2025Sep 30, 20252.0%-2.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q2 2025Jun 30, 20250.0%-1.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q1 2025Mar 31, 20254.0%+4.0 ptsQ3 2026 Reconciliation of Financial Information ↗
Q4 2024Dec 31, 20245.0%+12.0 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q3 2024Sep 30, 20244.0%+10.0 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q2 2024Jun 30, 20241.0%+6.0 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q1 2024Mar 31, 20240.0%+28.0 ptsQ4 & FY2025 Reconciliation of Financial Information ↗
Q4 2023Dec 31, 2023-7.0%–Q4 & FY2024 Reconciliation of Financial Information ↗
Q3 2023Sep 30, 2023-6.0%–Q4 & FY2024 Reconciliation of Financial Information ↗
Q2 2023Jun 30, 2023-5.0%–Q4 & FY2024 Reconciliation of Financial Information ↗
Q1 2023Mar 31, 2023-28.0%–Q4 & FY2024 Reconciliation of Financial Information ↗

Breakdown

What makes up organic Revenue Growth — Specialty Diagnostics

Cite this data

StockData. (2026). Thermo Fisher Scientific Organic Revenue Growth — Specialty Diagnostics (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/org-growth-pct-sd

See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.